-diabetic poly-neuropathy is one of the most common micro-vascular complications of type 2 diabetes mellitus -evidence indicates oxidative stress as one of the crucial factors involved in the pathology -diabetic patients with or without peripheral poly-neuropathy present alterations in the anti-oxidant defense system -individuals with diabetic poly-neuropathy exhibit reduced malon-dialdehyde levels -oxidative markers can be used as surrogate diagnostic tools and to monitor response to treatment
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Oxidative stress markers in cognitively intact patients with diabetic neuropathy

INTRODUCTION
Micro-vascular disease is considered to be one of the most common complications of type-2 diabetes mellitus (DM2). The subtle injuries involving the small blood vessels that supply nerves lead to diabetic poly-neuropathy (DPN) and are the risk factors for other neuro-psychiatric disorders such as cognitive impairment [1, 2] . DPN affects about one-third of the diabetic population. It causes a great impact on the patients' quality of life and increases the rate of morbidity and mortality [1, 3] . According to the literature, oxidative stress is considered as one of the main factors in the development of DM2 and its complications [4] .
Oxidative stress is usually defined as the process of imbalance between free radicals and antioxidants that favors the increase of free radicals [5] . The main free radicals are reactive oxygen species (ROS) and reactive nitrogen species (RNS). ROS includes radicals such as superoxide, hydroxyl, peroxyl and hydroperoxyl, whereas RNS comprises nitrite oxide [6] . Due to its great participation in the development of DM2
and its likely role in the pathogenesis of DPN, the oxidative stress profile must be investigated [7] .
Both DM2 and its complications are multifactorial, and so the pathogenesis of DPN is rather complex. It has not been well defined yet, but some studies point to several pathways that may lead a diabetic individual to develop PD, including hyperglycemia, dyslipidemia and impaired insulin signaling [8] . Currently, hyperglycemia is considered as one of the most described mechanisms. There is evidence that chronic hyperglycemia can cause cell damage through several pathways. First, excess glycolysis leads to mitochondrial electron transport chain overload and increased ROS and RNS [8] .
Through the polyol pathway, hyperglycemia increases cellular osmolarity by reducing the nicotinamide adenine phosphate dinucleotide NADPH, which, consequently, leads to oxidative stress [4] . Through the hexosamine pathway, hyperglycemia can cause inflammatory injury [8] . In addition, increased blood glucose may generate advanced late glycation end products (AGEs). In general, the latter causes the oxidation of biomolecules and irreversible tissue damage, including peripheral nerve damage [9] .
Recent studies have been conducted to verify the association between oxidative stress
and the development of DM2 or DPN [2] . Many of these studies evidence a relationship between oxidative stress and DM2.
In light of such evidence on the role of oxidative stress in the development of DM2 and its complications, the present study aims to evaluate the profile of oxidative stress in patients with DM2 and DPN and relate them to factors associated with the development of DPN.
MATERIALS AND METHODS
Study design
This is a cross-sectional study, with descriptive and inferential statistical analysis.
Patients and control subjects
The study protocol was approved by the Committee for Ethics in Research of the Federal University of Viçosa (CAAE 59855516.0.0000.5153). All subjects signed legal consent forms. Information on demographic characteristics, lifestyle habits and perceived stress level was also assessed.
We assessed a total of 42 male and female subjects at the ages ranging from 40 to 72 years. DM2 patients were selected in the Centro Estadual de Atenção Especializada in Viçosa, Minas Gerais, Brazil. DM2+DPN patients were selected at the neurology clinic in Viçosa. The diagnosis was confirmed by nerve conduction studies and the presence of peripheral neurological symptoms. The control group was composed of healthy subjects with no previous history of DM2 or DPN. Healthy individuals were recruited via the on-line news and mailing system of the Federal University of Viçosa. On the basis of clinical criteria, the subjects were distributed into three groups: control (n = 13), DM2 (n = 15) and DM2+ DPN (n = 14).
Subjects with renal, hepatic, autoimmune, and myelo-proliferative diseases, coagulation disorders, cancer, in a post-operative period or immobilized during a long time, and
those with metabolic syndrome were excluded from the study. All participants with Type 1 diabetes mellitus were also excluded. The individuals were classified as having DM2 if plasma glucose was equal to over 126 mg/dL, under fasting conditions, or if they were receiving oral anti-diabetics or insulin. The mini-mental state examination (MMSE) was performed according to Folstein et al., 1975 [10] .
Sample collection
Venous blood samples were taken from all subjects after fasting for 12 hours. Five milliliters of venous blood without anticoagulant were collected from each participant using Vacutainer® System tubes (Becton-Dickinson). The samples were centrifuged at 1.100 g for 15 minutes, for rapid serum separation. The serum aliquots were stored at -70ºC.
Laboratory measurements
The tissue damage marker Malondialdehyde (MDA), nitric oxide (NO), antioxidant mediators Glutathione S-transferase (GST) and total antioxidant capacity were measured, to evaluate the oxidative stress.
The lipid peroxidation (MDA) was measured by reactive substances with thiobarbituric acid (TBARS), according to the methodology proposed by Buege and Aust [11] . Thus, 200 μL of each sample were added to 400 μL of TBARS solution (15% TCA, 0.375% TBA and 0.25M HCl), vortexed for 10 seconds and placed in water bath, at 90°C, for 40 minutes. After cooling, the thiobarbituric acid reactive substances were extracted with the addition of 600 μL of n-butanol, followed by centrifugation at 3500 rpm, for 5 minutes. Finally, after centrifugation, 200 μL of the supernatants were removed and subjected to reading at 535 nm. TBARS values were expressed as malondialdehyde (MDA) ηmols per mg protein.
Nitric oxide was evaluated by the modified Griess method [12] . In this method, nitric is used as an indicator of nitric oxide synthesis and is detected by the Griess Reactive, composed of 1% sulfanilamide and 0.1% naphthylethylene diamine in 2.5% H3PO4.
Based on this method, 50 μL of serum was added to 96-well microplates containing 100 μL of the Griess Reagent. This mixture was incubated in the dark for 10 minutes, at
room temperature. After incubation, the Thermo Scientific Multiskan GO spectrophotometer, 570 nm wave, was used for analysis. The concentration of nitric oxide was measured using the standard curve with known concentrations (μM) of sodium nitrite.
The analysis of the enzymatic activity of GST was performed by the method described by Habig et al. [13] . In a Quartz cuvette, 682 μL of Phosphate buffer (0.1 M and pH 7.0) was pipetted along with 6 μL of CDNB 1-chloro-2,4-dinitrobenzene (0.1 M), 6 μL of sample and 6 μl of GSH solution (0.1 M).The reaction rate of the enzyme present in the samples was monitored at 340 nm in a spectrophotometer for 90 seconds to monitor the enzymatic kinetics. A blank was also made for the experiment, which had no addition of the sample and was used to verify the rate of non-enzymatic reactions. The enzyme activity was expressed in μmol min-1 g -1, where one unit of activity refers to the amount of enzyme that catalyzes the formation of 1 μmol of product per minute and per gram of sample, under the conditions of the assay.
The total antioxidant capacity (FRAP) was determined by the method described by Benzie and Strain [14] . The reaction was performed by adding10 μL of sample or standard, and 220 μL of the FRAP solution were added to polystyrene microplates. The microplates were incubated in the dark for 30 minutes.
Statistical analysis
The data were analyzed by the Graph Pad Prism version 7.0 software system, using oneway analysis of variance (ANOVA), followed by the Tukey test. The categorical variables (risk factors) were analyzed by the Chi-square contingency test. The Pearson's correlation coefficient was used to measure the linear association between two continuous variables.
The minimum size of the sample was defined using the coefficient of variation previously obtained for FRAP (21.6%) and GSH (20.2%) in the literature [15] , considering fifteen and twelve percent of variation around the average, respectively, with a minimum number of nine individuals per group. It was possible to verify statistical differences with a 5% level of significance [16] .
RESULTS & DISCUSSION
There were no significant correlations between the variables studied. Table 1 presents the characteristics of age, sex and body mass index of the three study groups, as well as the evaluation parameters of the oxidative stress profile and the result of the stress perceived by the participants. Table 2 displays data about medications and supplements (vitamins A, C, E) used by the participants in the DM2 and DM2+DPN groups. When uncontrolled, chronic hyperglycemia can lead to macrovascular and microvascular complications [7] . Polyneuropathy is considered to be one of the most severe and common microvascular complication [17] . One of the causes associated with the development of polyneuropathy in diabetic individuals is oxidative stress, which is defined as an imbalance process between ROS and antioxidants, with the occurrence of increased radical production and decreased rate of antioxidants [5, 17] .
In this study, we investigated the parameters related to oxidative stress in patients with DM2 and DPN. A decreased total antioxidant capacity was observed in the serum of patients with DM2 and DPN, when compared with participants considered normal in the control group. These findings suggest that patients with DM2 with or without DPN present alterations in the antioxidant defense system in relation to controls. Contrary to other studies, such as de Palem and Abraham (2015) [18] and Ganjifrockwala et al.
(2017) [19] , a significantly reduced MDA level was observed in the DM2+DPN group compared to the DM2 and control groups.
A C C E P T E D M A N U S C R I P T
The studied population didn't present a cognitive decline considering the data obtained with the MMSE (Table 1) and also the years of schooling of the participants. The characteristics of the participants that were considered in the present study include age, gender, BMI, perceived stress and MMSE. These factors may directly or indirectly affect the oxidative profile of an individual [20, 21, 22] . Age may alter the markers of oxidative stress, which, in its turn, will increase the risk of developing various diseases, including DPN [3, 20, 21] . Regarding gender, there is still controversy, but some authors found a significant difference in the profile of oxidative stress in female and male diabetic patients [23] , while others did not observe this difference [24] . Despite some controversies, BMI is considered as one of the factors that may also alter the markers of oxidative stress [22] . The results of our study show a significant difference between the control group and the DM2 group. But there was no statistical difference between the control group and the DM2+DPN group and the DM2 and DM2+ DPN groups showed no significant differences either. The difference between the control group and the DM2 group may help explain the relationship between obesity and DM2 development. There is lack of very consistent studies on the processes in which psychological stress participates in the development of DM2 and its complications, but some studies point to an association between perceived stress and DM2 [25] . In most of these studies, a high level of perceived stress was observed in DM2 patients when compared with nonpatients. The study by Thangavel et al. (2015) [26] concluded that perceived stress along with BMI can be considered as high risk factors for the development of hyperglycemia. Scientific evidence points the oxidative stress as one of the main factors for the cognitive decline [27] The reaction between NO and superoxide anion forms the peroxynitrite radical, which may damage macromolecules such as proteins and their functions [28] . In addition, the literature indicates that high NO production is considered an underlying factor in the pathogenesis of DPN [29] . Studies that evaluated the level of NO in DM2 patients present controversial results [30] . In some studies, the level of NO in diabetic groups increased, compared with non-diabetic subjects [28] . However, other studies have observed a decreased NO between the diabetic and control groups [31] . The present study was not able to establish a significant difference between the three groups in relation to NO.
MDA is involved in lipid peroxidation [29] and is one of the mostly used biomarkers in the evaluation of oxidative stress in patients with DM2 [25, 32] . In chronic diseases, such as DM2 and its complications, there is usually excessive formation of MDA [33] .
However, the present study presented decreased MDA in the DM2+PDN group in relation to the DM2 group and in the control group. No significant difference was observed between the DM2 group and the control group. This reduced MDA in patients with diabetes with neuropathy can be explained by some hypotheses that remain unclear. Among them, we can point out the daily use of alpha lipoic acid, vitamin A, C and E supplements [9] .
The daily use of vitamins A, C and E supplements is one of the strategies to treat or control DM2+DPN patients. So far, there is a dearth of information on the role of vitamin A and vitamin C supplements, but studies have already shown some benefits of vitamin E for diabetic patients with peripheral neuropathy [7, 34] , including decreased final products of lipid peroxidation, such as MDA [7, 34] . In addition to vitamin supplements, the study by Villegas-Rivera et al (2015) shows the effects of the drug simvastatin, which significantly reduces the MDA marker in patients with DM2+DPN [35] . Therefore, we can relate the results of our study with the vitamins A, C and E supplements ingested by some participants of the DM2+DPN group, as well as the significantly higher use of simvastatin, oral hypoglycemic agents and insulin [36] .
A significant FRAP decrease was observed in the DM2 and DM2+DPN groups compared to the control group. This marker is widely used for measuring total antioxidant capacity in DM2 patients [37] . Unlike other methods, FRAP provides us information not only on a specific antioxidant or enzyme, but on the overall profile of all antioxidants in the body [37] . A study conducted by Dasegowda and collaborators in a diabetic population presented results to those of the present study [38] . Another study conducted by Padel and colleagues also obtained reduced FRAP values in patients with DM2 compared to controls [37] . The FRAP decrease evidenced in the present study can corroborate the information about the changes in the antioxidant defense system in patients with DM2. However, no difference was observed for this marker between DM2
A C C E P T E D M A N U S C R I P T carriers with and without diabetic neuropathy. The non-significant difference found in the FRAP results for the DM2 and DM2+DPN groups may be associated with the daily use of significantly higher rates of vitamin A, C and E supplements in the DM2+DPN group [7] .
Glutathione is an enzyme present in almost all cells that plays a crucial role in the metabolism of several elements [5, 32] , mainly in the detoxification, by acting in the defense and protection of cells against free radicals [39] . In this study, no significant differences were found between patients with DM2 or DPN, compared with healthy individuals. Giriraja et al. found significantly lower levels of GST among individuals with DM2 with neuropathy, compared to the control group [33] . In addition, most studies evaluating GST in patients with DM2, with or without DPN, found a significantly reduced GD [2, 33] . Decreased GST in patients with DPN seems to be associated with nerve damage and neural apoptosis [40] . The present study did not present a significant difference between the three groups for GST, which can be explained, in part, by the supplementation of vitamins C and E ingested by patients with DM2+DPN, as well as the increased use of lipid-lowering and antidiabetic agents [34, 36] .
This study has a few limitations. First, the results of this study may not be completely generalizable because the sample was restricted. Second, data collection has some shortcomings that limited some interesting correlations of results, such as data on nonpharmacological interventions of participants with MD2. Third, lack of resource to evaluate other markers of oxidative stress.
The results obtained lead to the conclusion that DM2 patients with or without diabetic poly-neuropathy presented reduction of total antioxidant capacity in relation to healthy subjects, which may indicate greater oxidative stress in the diabetic patients studied.
The decrease in serum MDA levels in the group of diabetic patients with polyneuropathy may be related to the effect of the medications and to the supplementation of vitamins A and E, ingested by the patients. 
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